Figure 1. Selected deals between GSK and biotechs or academic institutions. GlaxoSmithKline plc created the Center of Excellence for External Drug Discovery (CEEDD) in 2005 and closed the unit in 2012. During that time, CEEDD formed 16 partnerships with entities that typically had molecules in stages ranging from discovery to Phase II. The graph excludes partnerships outside the scope of CEEDD, including technology, preventative vaccine and diagnostic deals. Source: BCIQ: BioCentury Online Intelligence; GSK